Context and Menarini Entered into a Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR + Elacestrant for Metastatic Breast Cancer
Shots:
- The companies collaborated to initiate P-Ib/II (ELONA) clinical PoC trial evaluating onapristone extended-release (ONA-XR) + elacestrant in patients with ER+, PR+ HER2- mBC who have prior been treated with a CDK4/6 inhibitor
- The trial is expected to be initiated in Q4’22. Additionally, Context will be responsible to sponsor the clinical trial and Menarini will supply elacestrant at no cost
- In a P-III trial, Elacestrant showed an improvement in PFS over SoC endocrine therapy in patients with ER+, HER2- mBC with a 30% reduction in risk of progression or death in all patients, 22% vs 9% of patients were alive and progression-free @12mos. after elacestrant treatment initiation in the overall population
Ref: GlobeNewswire | Image: Context Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
